

GlaxoSmithKline Pharmaceuticals Limited,
GSK House, Dr. Annie Besant Road, Worli
Mumbai - 400 030 (India)

T +91 22 2495 9595
F +91 22 2495 9494

27th July 2022

Mr. Manu Anand
506 B, The Aralias,
DLF Golf Links,
Sector-42, Gurgaon,
Haryana-122009

**Re: Your appointment for first term of five consecutive years as the
Independent Director of the Company.**

Dear Sir,

We are pleased to advise you that the Board of Directors of the Company have by have approved your appointment as the Independent Director of the Company, to hold office for first term of five years upto 15th May 2027, subject to approval of Members, on the terms and conditions contained herein and it would be;

A. Term

Your appointment is for first term of 5 years commencing from 16th May 2022 unless terminated earlier in accordance with the applicable law.

B. Committees

You have been appointed to the Audit & Risk Management Committee of the Board:

C. Role, Duties and Responsibilities

1. You will abide by the Code of Conduct applicable to the Independent Director of the Company as set out in Annexure - 1.
2. You will abide by the duties and responsibilities set out Annexure - 2.
3. While you are entitled to a training program, as set out below, you are expected to stay updated on how best to discharge your roles, responsibilities, duties and liabilities, as an Independent Director of the Company under applicable law, including keeping abreast of current changes and trends in economic, political, social, financial and legal and corporate governance practices.
4. The management expects its Independent Directors to:
 - (i) take decisions objectively and solely in the interests of the Company;
 - (ii) facilitate Company's adherence to high standards of ethics and corporate behavior;
 - (iii) facilitate existence of appropriate risk management/regulatory compliance policies;



GlaxoSmithKline Pharmaceuticals Limited,
GSK House, Dr. Annie Besant Road, Worli
Mumbai - 400 030 (India)

T +91 22 2495 9595
F +91 22 2495 9494

- (iv) guide the Board in monitoring the effectiveness of the Company's governance practices and to recommend changes, required if any;
- (v) guide the Board in monitoring and managing potential conflicts of interest of management, Board members and shareholders, including misuse of corporate assets and abuse in related party transactions;
- (vi) guide the Board in ensuring the integrity of the Company's accounting and financial reporting systems, including the independent audit, and that appropriate systems of control are in place, in particular, systems for risk management, financial and operational control, and compliance with the law and relevant standards;
- (vii) act on a fully informed basis, in good faith, with due diligence and care, and in the best interest of the Company and the shareholders; and
- (viii) comply with his/her duties and obligations under applicable law, particularly the Act and the equity listing agreement.

D. Performance Evaluation

Your reappointment or extension of term and your remuneration will be recommended by the Nominations & Remuneration Committee to the Board, pursuant to the performance evaluation carried out by the Board.

E. Remuneration

1. Your annual remuneration will be as under:

- (a) sitting fees for attending each meeting of the Board and its Committees as may be determined by the Board from time to time, and
 - (b) commission based on the performance of the Company and your performance evaluated by the Board of Directors payable at the end of each financial year.
2. You will be entitled to reimbursement of expenses including accommodation in the hotel, travelling and other out-of-pocket expenses incurred by you in connection with attending the Board Meeting or any Board Committee meeting or in relation to the business of the Company.
3. Pursuant to applicable law, you will not be entitled to any stock options.

F. Insurance

The Company will take an appropriate Directors' and officers' liability Insurance policy and pay the premium for the same. It is intended to maintain such Insurance cover for the term of your appointment, subject to the terms of such policy in force from time to time.



GlaxoSmithKline Pharmaceuticals Limited,
GSK House, Dr. Annie Besant Road, Worli
Mumbai - 400 030 (India)

T +91 22 2495 9595
F +91 22 2495 9494

G. Training

1. You will be entitled to the benefit of a training program to familiarize you with the business and affairs of the Company, growth plans, the peculiarities of the industry in which the Company operates its goals and expectations and long-term plans and objectives.
2. Such training program will also apprise you of your roles and responsibilities, expectations from the Board and senior management, your fiduciary duties and liabilities, and the Company's Code of Conduct and the Code of Business Ethics.

H. Miscellaneous

1. You will have access to confidential information, whether or not the information is marked or designated as "confidential" or "proprietary", relating to the Company and its business including legal, financial, technical, commercial, marketing and business related records, data, documents, reports, etc., client information, intellectual property rights (including trade secrets), ("Confidential Information").

You undertake to use reasonable efforts to keep confidential and to not disclose to any third party, such Confidential Information.

If any Confidential Information is required to be disclosed by you in response to any summons or in connection with any litigation, or in order to comply with any applicable law, order, regulation or ruling, then any such disclosure should be, to the extent possible, with the prior consent of the Board.

2. This letter and any dispute or claim arising out of, or in connection with it construed in accordance with and be governed by the laws of India. The courts of Mumbai alone and no other courts shall have the jurisdiction to entertain and try any disputes arising from and out of the provisions of this letter.
3. This letter may be signed by facsimile or in any number of counterparts, each of which is an original and all of which, taken together, constitutes one and the same instrument.

Please confirm your acceptance by signing, dating, and returning a copy of this letter to the Company.

Yours faithfully,



Ms. R. S. Karnad
Chairperson

Agreed and Accepted



Mr. Manu Anand

GlaxoSmithKline Pharmaceuticals Limited,
GSK House, Dr. Annie Besant Road, Worli
Mumbai - 400 030 (India)

T +91 22 2495 9595
F +91 22 2495 9494

Annexure 1

Guidelines for Professional Conduct

You will observe the professional conduct as an Independent Director as under:

1. Uphold ethical standards of integrity and probity.
2. Act objectively and constructively while exercising your duties.
3. Exercise your responsibilities in a bona fide manner in the interest of the Company.
4. Devote sufficient time and attention to your professional obligations for informed and balanced decision making.
5. Not allow any extraneous considerations that will vitiate your exercise of objective independent judgment in the paramount interest of the Company as a whole, while concurring in or dissenting from the collective judgment of the Board in its decision making.
6. Not abuse your position to the detriment of the Company or its shareholders or for the purpose of gaining direct or indirect personal advantage or advantage for any associated person.
7. Refrain from any action that would lead to loss of your independence.
8. Where circumstances arise which make you lose your independence, you must immediately inform the Board accordingly.
9. Assist the Company in implementing the best corporate governance practices.



GlaxoSmithKline Pharmaceuticals Limited,
GSK House, Dr. Annie Besant Road, Worli
Mumbai - 400 030 (India)

T +91 22 2495 9595
F +91 22 2495 9494

Annexure 2

Duties and Responsibilities

Your duties and responsibilities as an Independent Director are as under:

1. Assist in bringing an independent judgment to bear on the Board's deliberations especially on issues of strategy, performance, risk management, resources, key appointments and standards of conduct.
2. Bring an objective view in the evaluation of the performance of Board and management.
3. Scrutinise the performance of management in meeting agreed goals and objectives and monitor the reporting of performance.
4. Satisfy yourself on the integrity of financial information and that financial controls and systems of risk management are robust and defensible.
5. Safeguard the interests of all stakeholders, particularly the minority shareholders.
6. Balance the conflicting interest of the stakeholders.
7. Determine appropriate levels of remuneration of executive directors, key managerial personnel and senior management and have a prime role in appointing and where necessary recommend removal of executive directors, key managerial personnel and senior management.
8. Moderate and arbitrate in the interest of the Company as a whole, in situations of conflict between management and shareholder's interest.
9. Undertake appropriate induction and regularly update and refresh your skills, knowledge and familiarity with the Company.
10. Seek appropriate clarification or amplification of information and, where necessary, take and follow appropriate professional advice and opinion of outside experts at the expense of the Company.
11. Strive to attend all meetings of the Board and of the Board committees of which you are a member.
12. Participate constructively and actively in the committees of the Board in which you are chairperson or member.
13. Strive to attend the general meetings of the Company.
14. Where you have concerns about the running of the Company or a proposed action, ensure that these are addressed by the Board and, to the extent that they are not resolved, insist that your concerns are recorded in the minutes of the Board meeting.



GlaxoSmithKline Pharmaceuticals Limited,
GSK House, Dr. Annie Besant Road, Worli
Mumbai - 400 030 (India)

T +91 22 2495 9595

15. Keep yourself well informed about the Company and the external environment in which it operates.
16. Not to unfairly obstruct the functioning of an otherwise proper Board or Committee of the Board.
17. Pay sufficient attention and ensure that adequate deliberations are held before approving related party transactions and assure yourself that the same are in the interest of the Company.
18. Ascertain and ensure that the Company has an adequate and functional vigil mechanism and to ensure that the interests of a person who uses such mechanism are not prejudicially affected on account of such use.
19. Report concerns about unethical behaviour, actual or suspected fraud or violation of the Company's code of conduct or ethics policy.
20. Acting within your authority, assist in protecting the legitimate interests of the Company, shareholders and its employees.
21. Not disclose confidential information, including commercial secrets, technologies, advertising and sales promotion plans, unpublished price sensitive information, unless such disclosure is expressly approved by the Board or required by law.
22. Separate meeting of the Independent Director:
 - (1) As an Independent Director or the Company you shall hold at least one meeting of the Independent Director in a year; without the attendance of Non-Independent Directors and members of management and endeavour to attend the same;
 - (2) The meeting of the Independent Director shall :
 - a. Review the performance of non-independent directors and the Board as a whole;
 - b. Review the performance of the Chairperson of the company, taking into account the view of Executive Directors and Non-Executive Directors.
 - c. Assess the quality, quantity and timelines of flow of information between the Company management and the Board that is necessary for the Board to effectively and reasonably perform their duties.

Handwritten signature in blue ink

Handwritten signature in blue ink

